Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
No open-market purchases or sales by Gossamer Bio, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2021
Institutional positions in Gossamer Bio, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 133
- +6 vs. Q3 2021
- Shares held
- 58.8M
- +4.90M (+9.1%) vs. Q3 2021
- Total value
- $664.9M
- −$12.3M (−1.8%) vs. Q3 2021
- New holders
- 20
- 42 more added
- Sold out
- 14
- 42 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GOSS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 170 | $60.8M |
| Q1 2026 | 185 | $56.3M |
| Q4 2025 | 195 | $573.4M |
| Q3 2025 | 164 | $473.7M |
| Q2 2025 | 124 | $218.0M |
| Q1 2025 | 119 | $186.9M |
| Q4 2024 | 105 | $155.0M |
| Q3 2024 | 100 | $172.6M |
| Q2 2024 | 94 | $164.7M |
| Q1 2024 | 109 | $233.5M |
| Q4 2023 | 98 | $192.0M |
| Q3 2023 | 96 | $171.2M |
| Q2 2023 | 99 | $74.4M |
| Q1 2023 | 111 | $97.9M |
| Q4 2022 | 120 | $225.1M |
| Q3 2022 | 160 | $1.02B |
| Q2 2022 | 129 | $533.2M |
| Q1 2022 | 141 | $519.8M |
| Q4 2021 | 133 | $664.9M |
| Q3 2021 | 128 | $687.7M |
| Q2 2021 | 115 | $431.1M |
| Q1 2021 | 123 | $501.9M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Gossamer Bio, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of New York Mellon Corp | 228,196 | $2.58M | 0.00% | −60.0% | Reduced |
| Goldman Sachs Group Inc | 244,088 | $2.76M | 0.00% | −327,829−57.3% | Reduced |
| Bank of America Corp | 253,655 | $2.87M | 0.00% | +160,180+171.4% | Added |
| Two Sigma Advisers, LP | 265,200 | $3.00M | 0.01% | +61,600+30.3% | Added |
| Two Sigma Investments, LP | 332,251 | $3.76M | 0.01% | +142,891+75.5% | Added |
| Lord, Abbett & Co. LLC | 390,146 | $4.41M | 0.01% | +390,146 | New |
| Charles Schwab Investment Management Inc | 390,505 | $4.42M | 0.00% | +7,938+2.1% | Added |
| Ally Bridge Group (NY) LLC | 475,000 | $5.37M | 1.88% | −700,000−59.6% | Reduced |
| Parkman Healthcare Partners LLC | 546,421 | $6.18M | 1.40% | −240,449−30.6% | Reduced |
| Marshall Wace, LLP | 572,072 | $6.47M | 0.01% | +552,820+2,871.5% | Added |
| Northern Trust Corp | 598,089 | $6.76M | 0.00% | −2,348−0.4% | Reduced |
| OrbiMed Advisors LLC | 683,000 | $7.72M | 0.10% | +683,000 | New |
| Norges Bank | 724,800 | $8.20M | 0.00% | 00.0% | Unchanged |
| FMR LLC | 894,500 | $10.1M | 0.00% | 00.0% | Unchanged |
| Jacobs Levy Equity Management, Inc | 908,432 | $10.3M | 0.07% | −68,931−7.1% | Reduced |
| Woodline Partners LP | 977,823 | $11.1M | 0.16% | +977,823 | New |
| Geode Capital Management, LLC | 1,013,083 | $11.5M | 0.00% | +17,322+1.7% | Added |
| Kynam Capital Management, LP | 1,016,857 | $11.5M | 6.15% | +1,016,857 | New |
| Ikarian Capital, LLC | 1,166,933 | $13.2M | 3.78% | −185,000−13.7% | Reduced |
| Morgan Stanley | 1,221,855 | $13.8M | 0.00% | +967,952+381.2% | Added |
| Octagon Capital Advisors LP | 1,513,138 | $17.1M | 3.33% | 00.0% | Unchanged |
| Emerald Advisers, LLC | 1,770,919 | $20.0M | 0.74% | +254,916+16.8% | Added |
| Palo Alto Investors LP | 1,772,950 | $20.1M | 1.28% | 00.0% | Unchanged |
| Emerald Mutual Fund Advisers Trust | 1,805,305 | $20.4M | 0.72% | +227,558+14.4% | Added |
| Citadel Advisors LLC | 1,875,751 | $21.2M | 0.02% | +287,800+18.1% | Added |
| Artal Group S.A. | 2,358,968 | $26.7M | 0.78% | 00.0% | Unchanged |
| Boxer Capital, LLC | 2,462,358 | $27.8M | 1.11% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 2,962,242 | $33.5M | 0.06% | +80.0% | Added |
| Omega Fund Management, LLC | 3,164,835 | $35.8M | 5.06% | −155,773−4.7% | Reduced |
| State Street Corp | 3,292,091 | $37.2M | 0.00% | +629,325+23.6% | Added |
| BlackRock Inc. | 5,429,686 | $61.4M | 0.00% | +66,816+1.2% | Added |
| Vanguard Group Inc | 5,587,459 | $63.2M | 0.00% | +88,654+1.6% | Added |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 7,420,974 | $83.9M | 1.30% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −120,066−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −78,500−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −36,443−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −15,001−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,578−100.0% | Sold out |
| Liberty Wealth Management LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −1,735−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −1,378−100.0% | Sold out |
| Alaethes Wealth LLC | 0 | $0 | 0.00% | −750−100.0% | Sold out |
| Johnson Midwest Financial, LLC | 0 | $0 | 0.00% | −260−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −169−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| Meridian Wealth Partners, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |